On Friday, Shares of Amarin Corporation plc (NASDAQ:AMRN), surged 14.22% to $2.33.
Amarin Corporation declared a United States District Court has ruled that Amarin may promote to healthcare professionals certain uses of Amarin’s lead product, Vascepa®(icosapent ethyl) capsules, that are not covered by current FDA-approved labeling for the drug so long as the promotion is truthful and non-misleading. The Court declaration covers promotion of the FDA-reviewed and agreed effects of Vascepa demonstrated in the ANCHOR clinical trial of patients with persistently high triglycerides after statin therapy and use of peer-reviewed scientific publications that present the current state of scientific research related to the potential of Vascepa to reduce the risk of cardiovascular disease. Based on today’s ruling Amarin plans to start promotional activities consistent with the opinion as soon as possible.
Amarin Corporation plc, a biopharmaceutical company, focuses on developing and commercializing therapeutics for the treatment of cardiovascular diseases in the United States.
Shares of Johnson & Johnson (NYSE:JNJ), declined -0.22% to $98.85, during its last trading session.
Johnson & Johnson partner Ethicon Endo-Surgery Inc will get a second chance to hold rival surgical instrument maker Covidien Plc liable for allegedly infringing two patents on a specialized ultrasonic device that cuts and seals blood vessels, according to Reuters.
The U.S. Court of Appeals for the Federal Circuit on Friday said a lower court should not have canceled one of the patents on Ethicon’s surgical shears, and incorrectly ruled that Covidien did not infringe the other. The appeals court, however, upheld a ruling that Covidien did not copy the design of Ethicon’s device. Reuters Reports.
Johnson & Johnson, together with its auxiliaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices.
Finally, XOMA Corporation (NASDAQ:XOMA), ended its last trade with -1.31% loss, and closed at $0.77, hitting its lowest level.
XOMA Corporation declared John Varian, the Company’s Chief Executive Officer, is planned to present at the Wedbush PacGrow Healthcare Conference on Tuesday, August 11, 2015, at 2:30 p.m. EDT.
XOMA Corporation discovers and develops antibody-based therapeutics in the United States, Europe, and the Asia Pacific. The company’s lead product candidate comprises gevokizumab, a proprietary humanized allosteric-modulating monoclonal antibody that binds to the inflammatory cytokine interleukin-1 beta, which is in Phase III clinical trial for NIU and Behçet’s disease uveitis, pyoderma gangrenosum, active non-infectious anterior scleritis, autoimmune inner ear disease, and cardiovascular diseases, in addition to diseases under the neutrophilic dermatoses designation, Schnitzler syndrome, and other diseases; and various proof-of-concept studies comprising polymyositis/dermatomyositis, Schnitzler syndrome, and giant cell arteritis.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
